TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Combined Incidence of HPV-related Genital Warts, PIN, or Penile/Perianal/Perineal Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Seroprotected Participants for Anti-hemagglutination Inhibition (HI) Antibodies Against Vaccine-homologous H7N9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Seroconverted Participants for Anti-HI Antibodies Against Vaccine-homologous H7N9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Any Solicited Administration Site Events
Endpoint domain: Adverse events/effects
Primary endpoint: Radiographic width of bone labial to the implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-venous analgesic requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Treatment Response Based on Otoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance visual acuity with study lenses at Year 1 Follow-up - Sphere and Toric
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint angle of the limb contralateral to the brain injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Wrist flexor muscle spasticity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Quality of painless sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant Nutritional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of freedom from major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Chelsea Critical Care Physical Assessment Tool (CPAx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wolf motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency of progenitor exhausted CD8 T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: linear amount of root resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: volumetric amount of root resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to Infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intensity of abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: intensity of stool frequency and consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: intensity of abdominal distention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Posttraumatic Stress Disorder Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of NTM-001
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of NTM-001
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ of NTM-001
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Depression scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Well-Being scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: occurrence of respiratory complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Receptive Language Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expressive Language Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Core Language Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with a surgical diagnosis of parametrial endometriosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of significant ultrasonographic concomitant DE nodules predicting surgical involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of significant ultrasonographic indirect DE signs predicting surgical involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: NIR-fluorescence tumour to dysplasia ratio (TDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Admission to Intensive Care Unit
Endpoint domain: Mortality/survival
Primary endpoint: Physical mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Minnesota Living with Heart Failure (MLHF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of patients with SARS-CoV-2 viral load <32
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUCinf) of Aducanumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of Aducanumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in clinical performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with chronic post-leptospirosis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T and NK lymphocyte reconstitution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine profiles (Th1, Th2 or Th17)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of days without nighttime heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Taste sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central nervous system (CNS) clinical benefit rate (CBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: sensitivity of Contrast-Enhanced Mammography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity of Contrast-Enhanced Mammography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kangaroo position days at home
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Decrease of performance during pulmonary rehabilitation session
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Occurrence of pulmonary exacerbation
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Life (QoL) evaluated with EuroQol-5D
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life (QoL) evaluated with RAND SF-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum exposure in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Terminal elimination half life in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in knowledge about gun violence
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Attitudes about firearms safety counseling
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Confidence about firearms safety counseling
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Behaviors with Clients
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Behaviors with Clients in last month
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in the Generalized Anxiety Disorder 7-item Scale (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to recovery in each instrumental activity of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of arrested dental caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total corneal staining with fluorescein (Oxford Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency and severity of treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Xenon MRI Red Blood Cell (RBC) percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in cardiogenic oscillation amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive margin conversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance (Specificity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance (Sensitivity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Productivity Rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: System usability and satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pregnancy Mobility Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maternal Postpartum Quality of Life Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Objective Response (confirmed complete response [CR] or confirmed partial response [PR])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of IL-8+ initial T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Specificity of IL-8+ initial T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cutoff value of IL-8+ initial T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with adverse events (AEs) and serious adverse events (SAEs) and their severity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with discontinuations of study treatment due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Histopathological scoring of pancreatic duct biopsy specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma proteome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time-to-symptom-onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of patients at target range at 13 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of patients at target range at 26 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neck circumference measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cervical spine range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Maximum Voluntary Isometric Contraction Testing (MVIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in speed for Peak Revolutions per minute (RPM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in speed for completion of 60 revolutions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of neoantigen identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of vaccine generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of NeoVax
Endpoint domain: Adverse events/effects
Primary endpoint: Number of cases without facial nerve weakness post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pharmacists' adherence to the intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participants' responsiveness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of the recruitment process
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of the data collection process
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ganglion cell thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients on Maximum dose Irbesartan therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capability to self-administer antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anal Incontinence Impact on Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Anal Incontinence Impact on Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diagnostic performance of 68Ga-DOTA-dPNE PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Skeletal muscle and appendicular muscle mass measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand Grip Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-Meter Walk Gait Speed Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence rate of methotrexate treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of patients with high serum neurofilament light (sNfL) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in nighttime blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in 10-year atherosclerotic cardiovascular disease risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of electrograms per map
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of symptomatic malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Residual Cancer Burden 0/1 rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Patient Centered Outcome Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Parkinson's Disease Knowledge Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Health Education Impact Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Care Transitions Measure (CTM3)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Deterioration in renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hyperkalemia or symptomatic hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Questionnaire (Evaluation of Satisfaction with Medication, Ocular tolerance)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under concentration-time curve from time zero to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rhodes index of nausea, vomiting and retching (RINVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Peak increase in COVID-19 Sign and Symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient global impression of function
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Reported Outcomes Information System - Sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of subjects with complete and partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FACE-Q score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline of WHODAS2.0 questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Protocol Review Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Protocol Review Completion Rate Within 35 Days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of Acceptability of Intervention Measure (AIM) Scores of 10 or Greater
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportions of participants surviving at the landmark timepoints of 12, 24, and 36 months after NIVO/IPI/PBC initiation
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity of SenseToKnow for autism detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of SenseToKnow for autism detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Covid-19 Phobia Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Infusion-related reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Assessment of Constipation Symptoms (PAC-SYM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Medication adherence - proportion of participants with presence of tenofovir in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication adherence - proportion who have received all ART prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: clinical benefit response (CBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of platelet-leukocyte aggregates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Client Satisfaction Questionnaire-8 (CSQ-8) item mean score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of attained goals using Goal Attainment Scaling (GAS)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: report of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of EUROSTEM Femoral Stem
Endpoint domain: Adverse events/effects
Primary endpoint: Asthma severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in mean daytime ambulatory systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Health Action Process Approach Battery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: subjective dry mouth score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Cardiovascular risk (Framingham risk score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative incidence of grade III to IV aGVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma concentration-time curve within a dosing interval AUC(TAU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration AUC(0-T)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of patients achieving the collection of ≥5×10^6 CD34+ cells/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Urinary Distress Inventory (UDI-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Overactive Bladder Symptom Score (OABSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Management of pain following surgical procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxidative burst activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Genetic testing results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Composite Language Score at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Composite Motor Score at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Composite Cognitive Score at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Trials Chosen for Hard Task
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Oestradiol (E2) level in blood serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Progesterone level in blood serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Superoxide dismutase (SOD) activity level in follicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catalase activity level in follicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes